BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37552303)

  • 1. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
    Neilan TG; Quinaglia T; Onoue T; Mahmood SS; Drobni ZD; Gilman HK; Smith A; Heemelaar JC; Brahmbhatt P; Ho JS; Sama S; Svoboda J; Neuberg DS; Abramson JS; Hochberg EP; Barnes JA; Armand P; Jacobsen ED; Jacobson CA; Kim AI; Soumerai JD; Han Y; Friedman RS; Lacasce AS; Ky B; Landsburg D; Nasta S; Kwong RY; Jerosch-Herold M; Redd RA; Hua L; Januzzi JL; Asnani A; Mousavi N; Scherrer-Crosbie M
    JAMA; 2023 Aug; 330(6):528-536. PubMed ID: 37552303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
    Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
    Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.
    Livi L; Barletta G; Martella F; Saieva C; Desideri I; Bacci C; Del Bene MR; Airoldi M; Amoroso D; Coltelli L; Scotti V; Becherini C; Visani L; Salvestrini V; Mariotti M; Pedani F; Bernini M; Sanchez L; Orzalesi L; Nori J; Bianchi S; Olivotto I; Meattini I
    JAMA Oncol; 2021 Oct; 7(10):1544-1549. PubMed ID: 34436523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
    Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
    Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
    Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
    BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
    Chotenimitkhun R; D'Agostino R; Lawrence JA; Hamilton CA; Jordan JH; Vasu S; Lash TL; Yeboah J; Herrington DM; Hundley WG
    Can J Cardiol; 2015 Mar; 31(3):302-7. PubMed ID: 25662284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial.
    Assmus B; Walter DH; Seeger FH; Leistner DM; Steiner J; Ziegler I; Lutz A; Khaled W; Klotsche J; Tonn T; Dimmeler S; Zeiher AM
    JAMA; 2013 Apr; 309(15):1622-31. PubMed ID: 23592107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
    van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
    JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
    Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
    Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
    Hamidian M; Foroughinia F; Haghighat S; Attar A; Haem E
    J Oncol Pharm Pract; 2023 Sep; 29(6):1306-1316. PubMed ID: 35975564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.